How to Interpret a Diffusion Capacity of the Lung for Carbon Monoxide
Mar 7, 2017 · The diffusion capacity of the lung for carbon monoxide (DLCO) is used to measure the body's ability to transfer oxygen across the alveolar-capillary membrane. [1] Internists use this test to ...
DLco, Pulmonary Hypertension, and Idiopathic Pulmonary Fibrosis
Apr 12, 2007 · Can diffusion capacity be used as a measure of pulmonary hypertension in patients with idiopathic pulmonary fibrosis?
ERS/ATS Lung Guidelines Endorse Global Lung Initiative
Nov 28, 2022 · They identify commonly applied reference equations for interpreting diffusion capacity for carbon monoxide (DLCO) and lung volumes but stop short of endorsing any one equation over another.
Preoperative Evaluation of the Lung Cancer Resection Candidate
The ERS/ESTS guidelines state that DLCO should be routinely measured during preoperative evaluation of lung resection candidates, regardless of whether the spirometric evaluation is abnormal.
Bleomycin Being Underdosed in Advanced Germ Cell Tumors?
Feb 21, 2011 · A study of bleomycin toxicity showed that asymptomatic drops in lung function scores caused 20% of bleomycin doses to be missed and 20% of patients to receive less than their planned …
Long-Term Data Support Valve Value for Emphysema - Medscape
Sep 11, 2024 · In the current study, the researchers reviewed 5-year data from 52 of the 190 adults with severe emphysema who were originally randomized to treatment with the Zephyr valve or standard …
301 Moved Permanently
Apache/2.4.38 (Debian) Server at pftforum.com Port 80
Index of /blog/wp-content/uploads/2017/02 - pftforum.com
Index of /blog/wp-content/uploads/2017/02 Index of /blog/wp-content/uploads/2017/02
Upadacitinib Outperforms Mycophenolate in SSc-ILD Treatment
Jun 13, 2025 · The change in DLCO (as a percentage of the predicted value) at 52 weeks was -62.7 mL in the upadacitinib group and -93.3 mL in the mycophenolate group.
Anti-Ro/SSA Antibodies Have Potential to Predict ILD in SSc
Jun 14, 2024 · They also determined that anti-Ro/SSA antibodies are a risk factor for lower DLCO values in patients with ILD, with a regression coefficient of −1.93.